233,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This book provides a critical overview of the advances being made towards overcoming biological barriers through the contribution of nanosciences and nanotechnologies. Overcoming these barriers is of primary importance for solving the problems of many current drugs and vaccines and it is also especially relevant for the commercial exploitation of new therapeutic strategies i.e. gene and cellular therapies. Despite important information that has been covered in recently published books related to nanomedicine (mainly oriented towards technologies and applications), there is still an important…mehr

Produktbeschreibung
This book provides a critical overview of the advances being made towards overcoming biological barriers through the contribution of nanosciences and nanotechnologies. Overcoming these barriers is of primary importance for solving the problems of many current drugs and vaccines and it is also especially relevant for the commercial exploitation of new therapeutic strategies i.e. gene and cellular therapies. Despite important information that has been covered in recently published books related to nanomedicine (mainly oriented towards technologies and applications), there is still an important gap related to the relationship between the chemical properties of nanobiomaterials and their interaction with the biological environment. Thus, this comprehensive new book is presented with a clear and organised structure dedicated to the different biological barriers relevant for drug delivery applications and will focus on (i) mechanistic issues related to the interaction between drug delivery systems and biological barriers (ii) the analysis of the critical factors determining the efficacy of nanobiomaterials for specific applications. Moreover, this field has become highly multidisciplinary over the last decade, leading to the development of new products, as well as to significant advances from the regulatory point-of-view. The book will also provide an up-to-date view on these regulatory aspects and on the clinical relevance of nanomedicine. The book will be essential reading for pharmaceutical scientists working in industry and academia and will also be of interest for other scientists from a variety of areas including chemistry, biology, biochemistry and immunology.
Autorenporträt
M.J. Alonso has a long-track record of experience (more than 25 years) in the development of nanocarriers for overcoming biological barriers. Her contributions have not only been scientifically relevant (200 publications, more than 30 relevant projects) but have also led to several patents and to the development of a product under clinical evaluation. Noemi Stefania Csaba holds a research and teaching position at the University of Santiago de Compostela at the Department of Pharmaceutical Technology, Nanobiofar Group. She obtained her PhD Degree in 2005 at the University of Santiago de Compostela in the field of nanomedicine and nanotechnology and worked as a post-doctoral research fellow at the Swiss Federal Institute of Technology (ETH Zurich, 2005-2007). Noemi Csaba is the author of more than 20 scientific articles published in internationally recognised journals, several book chapters, two patents and more than 30 presentations and international symposia. Her main research interests and expertise are vaccine delivery, gene therapy, targeted nanocarriers , nanotechnology and nanomedicine in cancer research.